TIDMAREC

RNS Number : 0629K

Arecor Therapeutics PLC

27 August 2021

Arecor Therapeutics plc

("Arecor", the "Company" or the "Group")

APPOINTMENT OF GRANT THORNTON AS AUDITOR

Cambridge, UK, 27 August 2021: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that Grant Thornton UK LLP ("Grant Thornton") have been appointed as the Group's auditor, with immediate effect. Lakin Rose Limited has resigned as the auditor of Arecor Limited.

The Board's decision to appoint auditors for the Group was made following a consultation process. Grant Thornton was chosen based on their public company expertise, reputation and experience. Lakin Rose has confirmed that it is not aware of any circumstances connected with its cessation as auditor of Arecor Limited that it considers should be brought to the attention of the Board, creditors or shareholders.

In accordance with section 327(c) of the Corporations Act 2001, a resolution will be tabled at the Company's 2021 Annual General Meeting to ratify the appointment of Grant Thornton as the Group's auditor.

The Board of Directors would like to take this opportunity to thank Lakin Rose UK LLP for their assistance and services to Arecor Limited.

This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR").

-ENDS-

For more information, please contact:

 
 Arecor Therapeutics plc   www.arecor.com 
 
 
 Dr Sarah Howell, Chief Executive Officer   Tel: +44 (0) 1223 426060 
                                             Email: info@arecor.com 
 
 Susan Lowther, Chief Financial Officer     Tel: +44 (0) 1223 426060 
                                             Email: info@arecor.com 
 
 Mo Noonan, Communications                  Tel: +44 (0) 7876 444977 
                                             Email: mo.noonan@arecor.com 
 
 Panmure Gordon (UK) Limited (NOMAD 
  and Broker) 
 Freddy Crossley, Emma Earl (Corporate      Tel: +44 (0) 20 7886 2500 
  Finance) 
  Rupert Dearden (Corporate Broking) 
 
 Consilium Strategic Communications 
 Chris Gardner, David Daley, Angela         Tel: +44 (0) 20 3709 5700 
  Gray                                       Email: arecor@consilium-comms.com 
 

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical group transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat(TM), we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat(TM) platform is supported by an extensive patent portfolio.

For further details please see our website, www.arecor.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCPRMTTMTJTBLB

(END) Dow Jones Newswires

August 27, 2021 08:40 ET (12:40 GMT)

Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Arecor Therapeutics Charts.
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Arecor Therapeutics Charts.